Literature DB >> 4321899

Carcinosarcomas and mixed mesodermal tumors of the ovary.

L P Dehner, H J Norris, H B Taylor.   

Abstract

Entities:  

Mesh:

Year:  1971        PMID: 4321899     DOI: 10.1002/1097-0142(197101)27:1<207::aid-cncr2820270129>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  8 in total

Review 1.  Ovarian tumors. A review.

Authors:  R E Scully
Journal:  Am J Pathol       Date:  1977-06       Impact factor: 4.307

2.  Cytogenetic, morphologic and oncogene analysis of a cell line derived from a heterologous mixed mullerian tumor of the ovary.

Authors:  J L Becker; P R Papenhausen; R H Widen
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-05       Impact factor: 2.416

3.  Histogenesis of ovarian malignant mixed mesodermal tumours.

Authors:  T J Clarke
Journal:  J Clin Pathol       Date:  1990-04       Impact factor: 3.411

4.  Establishment and characterization of the NEYS cell line derived from carcinosarcoma of human ovary with special reference to the susceptibility test of anticancer drugs.

Authors:  Yoshiaki Ide; Taka Nakahara; Masanori Nasu; Noriko Tominaga; Akihiro Ohyama; Toshiaki Tachibana; Makoto Yasuda
Journal:  Hum Cell       Date:  2009-06-23       Impact factor: 4.174

5.  On the histogenesis and morphology of ovarian carcinomas.

Authors:  G Dallenbach-Hellweg
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

6.  Sarcoma-like mural nodules in cystic serous ovarian tumours.

Authors:  T J Clarke
Journal:  J Clin Pathol       Date:  1987-12       Impact factor: 3.411

7.  Primary malignant mixed müllerian mesodermal tumor mimicking a rectosigmoid carcinoma: a case report and review of the literature.

Authors:  Sakshi Kapur; Levin Miles
Journal:  Case Rep Oncol Med       Date:  2014-02-10

8.  Endometriosis Malignant Transformation Review: Rhabdomyosarcoma Arising From an Endometrioma.

Authors:  Camran Nezhat; Mailinh Vu; Nataliya Vang; Kristen Ganjoo; Amer Karam; Ann Folkins; Azadeh Nezhat; Farr Nezhat
Journal:  JSLS       Date:  2019 Oct-Dec       Impact factor: 2.172

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.